{"mainPropery":{"diseaseId":9728,"diseaseName":"Myotonic dystrophy type 2","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9728/myotonic-dystrophy-type-2","synonyms":["Dystrophia myotonica type 2","DM2","Proximal myotonic myopathy","PROMM","Myotonic myopathy, proximal","Ricker syndrome"],"synonyms-with-source":[{"name":"Dystrophia myotonica type 2"},{"name":"DM2"},{"name":"Proximal myotonic myopathy"},{"name":"PROMM"},{"name":"Myotonic myopathy, proximal"},{"name":"Ricker syndrome"}],"identifiers":[{"identifierType":"OMIM","identifierId":"602668"},{"identifierType":"ORPHANET","identifierId":"606"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":8,"diseaseTypeName":"Endocrine Diseases","source":"Orphanet"},{"diseaseTypeId":9,"diseaseTypeName":"Eye diseases","source":"Orphanet"},{"diseaseTypeId":24,"diseaseTypeName":"Male Reproductive Diseases"},{"diseaseTypeId":15,"diseaseTypeName":"Musculoskeletal Diseases"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":255,"resourceName":"Myotonic Dystrophy Foundation","abbreviation":"","address1":"1004-A O'Reilly Avenue","address2":"","address3":"","address4":"","address5":"","city":"San Francisco","state":"CA","zip":"94129","country":"United States","phone":"+1-415-800-7777","tty":"","tollFree":"1-86-MYOTONIC  (1-866-968-6642)","fax":"","email":"info@myotonic.org","url":"https://www.myotonic.org","freeText":""},{"resourceID":935,"resourceName":"Muscular Dystrophy Association","abbreviation":"MDA","address1":"222 S Riverside Plaza","address2":"Suite 1500","address3":"","address4":"","address5":"","city":"Chicago","state":"IL","zip":"60606","country":"United States","phone":"","tty":"","tollFree":"1-833-275-6321 (Helpline)","fax":"","email":"resourcecenter@mdausa.org","url":"https://www.mda.org","freeText":""},{"resourceID":936,"resourceName":"Muscular Dystrophy UK","abbreviation":"","address1":"61A Great Suffolk Street","address2":"","address3":"","address4":"","address5":"","city":"London","state":"","zip":" SE1 0BU","country":"United Kingdom","phone":" (+44) 0 020 7803 4800","tty":"","tollFree":"0800 652 6352 (Helpline)","fax":"","email":"info@musculardystrophyuk.org","url":"https://www.musculardystrophyuk.org/","freeText":""},{"resourceID":2339,"resourceName":"Myotonic Dystrophy Support Group","abbreviation":"","address1":"19-21 Main Road","address2":"Gedling","address3":"Nottingham","address4":"NG4 3HQ","address5":"","city":"","state":"","zip":"","country":"United Kingdom","phone":"0808 169 1960","tty":"","tollFree":"","fax":"","email":"contact@mdsguk.org","url":"http://www.myotonicdystrophysupportgroup.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/602668' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=myotonic%5BTitle%5D+AND+dystrophy%5BTitle%5D+AND+type%5BTitle%5D+AND+2%5BTitle%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Myotonic dystrophy type 2. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition=myotonicdystrophy' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Myotonic dystrophy type 2. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":250,"resourceId":1091,"resourceName":"Myotonic dystrophy","descriptionText":"Mulders SAM et al., <a href='http://hmg.oxfordjournals.org/content/19/R1/R90.full.pdf ' target='_blank'>Molecular therapy in myotonic dystrophy: Focus on RNA gain-of-function</a>. <em>Human Molecular Genetics</em>. 2010:19(1):R90-R97.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Selected Full-Text Journal Articles"},{"id":1402,"resourceId":1091,"resourceName":"Myotonic dystrophy","descriptionText":"<a href='https://www.mda.org/disease/myotonic-muscular-dystrophy' target='_blank'>The Muscular Dystrophy Association</a> (MDA) provides additional information about myotonic dystrophy. Click on the link to view this information.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0752354' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/357/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=606' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1466/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1539,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ResearchTrials_ResearchProjects_Simple.php?lng=EN&LnkId=545&Typ=Pat' target='_blank'>Orphanet</a> lists European clinical trials, research studies, and patient registries enrolling people with this condition.&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1541,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ClinicalLabs_Search_Simple.php?lng=EN&LnkId=545&Typ=Pat' target='_blank'>Orphanet</a> lists international laboratories offering diagnostic testing for this condition.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1549,"resourceId":2177,"resourceName":"National Human Genome Research Institute","descriptionText":"The <a href='http://www.genome.gov/25521207' target='_blank'>National Human Genome Research Institute's</a> (NHGRI) website has an information page on this topic. NHGRI is part of the National Institutes of Health and supports research on the structure and function of the human genome and its role in health and disease.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1651,"resourceId":255,"resourceName":"Myotonic Dystrophy Foundation","descriptionText":"<a href='http://www.myotonic.org/what-dm/start-here' target='_blank'>Myotonic Dystrophy Foundation</a> provides additional information about Myotonic dystrophy type 2.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:602668' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Myotonic dystrophy type 2. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Myotonic dystrophy type 2:<br />\r\n<a href='https://www.urmc.rochester.edu/neurology/national-registry.aspx' target='_blank'>National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy</a><br /><a href='https://myotonicregistry.patientcrossroads.org/index.php' target='_blank'>The Myotonic Dystrophy Family Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":520,"questionText":"What is myotonic dystrophy type 2?","answerText":"<strong>Myotonic dystrophy</strong> <strong>type 2, </strong>one of the two types of <a href=\"http://rarediseases.info.nih.gov/GARD/Disease.aspx?diseaseID=10419\" target=\"_blank\">myotonic dystrophy</a><strong>,</strong> is an inherited muscular dystrophy that affects the muscles and other body systems (e.g., heart, eyes, and pancreas). It is characterized by prolonged muscle tensing (<a href=\"http://www.ninds.nih.gov/disorders/myotonia/myotonia.htm\" target=\"_blank\">myotonia</a>) as well as muscle weakness, pain, and stiffness. Signs and symptoms usually develop during a person's twenties or thirties. Muscles in the neck, fingers, elbows, and hips are typically affected; facial and ankle muscles are less commonly involved.[348] The severity of myotonic dystrophy type 2 varies widely among affected people, even among family members.[346] It is inherited in an <a href=\"http://www.nlm.nih.gov/MEDLINEPLUS/ency/article/002049.htm\" target=\"_blank\">autosomal dominant pattern</a> and is caused by <a href=\"http://www.genome.gov/glossary.cfm?key=mutation\" target=\"_blank\">mutations</a> in the <em><a href=\"http://ghr.nlm.nih.gov/gene=cnbp\" target=\"_blank\">CNBP</a></em> gene.[346] Treatment is based on each person's specific signs and symptoms.","dateModified":"2014-02-10T12:53:00"},"basicQuestions":[{"questionId":521,"questionText":"What are the signs and symptoms of myotonic dystrophy type 2?","answerText":"Myotonic dystrophy type 2 is characterized by progressive muscle wasting and weakness. Symptoms typically begin in a person's twenties. People with this condition often have prolonged muscle contractions (<a href=\"http://www.ninds.nih.gov/disorders/myotonia/myotonia.htm\" target=\"_blank\">myotonia</a>) and are not able to relax certain muscles after use. For example, a person may have difficulty releasing their grip on a doorknob or handle. Also, affected people may have slurred speech; temporary locking of their jaw; and muscle pain and weakness that mainly affects the neck, shoulders, elbows, and hips. Less common symptoms include abnormalities of the electrical signals that control the heartbeat (cardiac conduction defects); clouding of the lens in the eyes (<a href=\"http://www.nei.nih.gov/health/cataract/cataract_facts.asp\" target=\"_blank\">cataracts</a>); and <a href=\"http://www.nlm.nih.gov/medlineplus/diabetes.html\" target=\"_blank\">diabetes</a>. Males may experience balding and infertility. The severity of symptoms varies among affected people. Compared to <a href=\"http://rarediseases.info.nih.gov/GARD/Condition/8310/Myotonic_dystrophy_type_1.aspx\" target=\"_blank\">myotonic dystrophy type 1</a>, type 2 is milder and does not necessarily shorten a person's lifespan.[347][348]","dateModified":"2014-02-10T17:47:00","resourceClassificationName":"Symptoms","references":[{"referenceId":347,"authors":"","articleTitle":"Myotonic dystrophy","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"November 2010","url":"http://ghr.nlm.nih.gov/condition=myotonicdystrophy","dateAccessed":"2011-05-11T00:00:00"},{"referenceId":348,"authors":"Dalton JC, Ranum LPW, and Day JW","articleTitle":"Myotonic Dystrophy Type 2","bookWebsiteJournalTitle":"GeneReviews","date":"July 3, 2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1466/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":522,"questionText":"What causes myotonic dystrophy type 2?","answerText":"Mutations in the <a class=\"link-dapple\" title=\"C N B P\" href=\"http://ghr.nlm.nih.gov/gene=cnbp\"><span><em>CNBP</em></span></a> gene cause myotonic dystrophy type 2. The exact function of this gene is not known. The protein made by the <em>CNBP</em> gene is mainly found in the heart and in skeletal muscles, where it probably helps regulate the function of other genes.[347] <br />\r\n<br />\r\nIn people with myotonic dystrophy type 2, a short piece of DNA is abnormally repeated many times, forming an unstable area of the gene. The mutated gene makes an altered version of messenger RNA (mRNA), which is a copy of the gene that is normally used for protein production. The abnormal mRNA forms clumps inside the cell that interfere with the production of many proteins. These changes prevent cells in muscles and other tissues from functioning normally, leading to the signs and symptoms of myotonic dystrophy.[346][347]","dateModified":"2014-02-10T13:01:00","resourceClassificationName":"Cause","references":[{"referenceId":346,"authors":"","articleTitle":"Learning About Myotonic Dystrophy","bookWebsiteJournalTitle":"National Human Genome Research Institute (NHGRI)","date":"June 4, 2012","volume":"","pages":"","url":"http://www.genome.gov/25521207","dateAccessed":"2015-04-22T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":347,"authors":"","articleTitle":"Myotonic dystrophy","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"November 2010","url":"http://ghr.nlm.nih.gov/condition=myotonicdystrophy","dateAccessed":"2011-05-11T00:00:00"}]},{"questionId":523,"questionText":"How is myotonic dystrophy type 2 inherited?","answerText":"Myotonic dystrophy type 2 is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> pattern, which means one copy of the altered gene in each cell is enough to cause symptoms of the condition. In most cases, an affected person has one affected parent.<br />\r\n<br />\r\nAs myotonic dystrophy is passed from one generation to the next, it generally begins earlier in life and signs and symptoms become more severe. This phenomenon is called anticipation. The cause of the anticipation in families with myotonic dystrophy type 2 is unknown.[346][347]","dateModified":"2014-02-10T13:04:00","resourceClassificationName":"Inheritance","references":[{"referenceId":346,"authors":"","articleTitle":"Learning About Myotonic Dystrophy","bookWebsiteJournalTitle":"National Human Genome Research Institute (NHGRI)","date":"June 4, 2012","volume":"","pages":"","url":"http://www.genome.gov/25521207","dateAccessed":"2015-04-22T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":347,"authors":"","articleTitle":"Myotonic dystrophy","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"November 2010","url":"http://ghr.nlm.nih.gov/condition=myotonicdystrophy","dateAccessed":"2011-05-11T00:00:00"}]},{"questionId":524,"questionText":"How is myotonic dystrophy type 2 diagnosed?","answerText":"Myotonic dystrophy is diagnosed by doing a physical exam. A physical exam can identify the typical pattern of muscle wasting and weakness and the presence of myotonia. A person with myotonic dystrophy may have a characteristic facial appearance of wasting and weakness of the jaw and neck muscles. Men may have frontal balding.[346] <br />\r\n<br />\r\nThere are several laboratory tests that can be used to clarify the clinical diagnosis of myotonic dystrophy. One test, called electromyography (EMG), involves inserting a small needle into the muscle. The electrical activity of the muscle is studied and usually shows characteristic patterns of muscle electrical discharge.[346] The definitive test for myotonic dystrophy type 2&nbsp;is a genetic test. For this test, certain cells within the blood are analyzed to identify a change (mutation) in the <a class=\"link-dapple\" title=\"C N B P\" href=\"http://ghr.nlm.nih.gov/gene=cnbp\" target=\"_blank\"><span><em>CNBP</em></span></a> gene. [346]<br />\r\n<br />\r\nThe University of Washington provides more information on&nbsp;genetic testing for&nbsp;myotonic dystrophy type 2 in their publication titled, \"<a href=\"http://depts.washington.edu/neurolog/images/neurogenetics/myotonic.pdf\" target=\"_blank\">Myotonic Dystrophy: Making an Informed Choice About Genetic Testing</a>.\"","dateModified":"2015-04-22T00:00:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":346,"authors":"","articleTitle":"Learning About Myotonic Dystrophy","bookWebsiteJournalTitle":"National Human Genome Research Institute (NHGRI)","date":"June 4, 2012","volume":"","pages":"","url":"http://www.genome.gov/25521207","dateAccessed":"2015-04-22T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":525,"questionText":"How might myotonic dystrophy type 2 be treated?","answerText":"There is currently no treatment available to stop or slow the progression of myotonic dystrophy type 2. Management options depend on the symptoms that each affected person has, and aim to treat each specific symptom. For example:[348]\r\n<ul>\r\n    <li>Ankle-foot braces, wheelchairs, or other assistive devices may be used as needed for weakness</li>\r\n    <li><a href=\"https://www.heart.org/HEARTORG/Conditions/Arrhythmia/PreventionTreatmentofArrhythmia/Defibrillation_UCM_305002_Article.jsp\" target=\"_blank\">Defibrillator</a> placement may be needed for arrhythmias</li>\r\n    <li><a href=\"https://www.nei.nih.gov/health/cataract/cataract_facts.asp\" target=\"_blank\">Cataracts</a> can be removed for those with impaired vision</li>\r\n    <li><a href=\"http://my.clevelandclinic.org/services/testosterone_replacement_therapy/hic_testosterone_replacement_therapy.aspx\" target=\"_blank\">Testosterone replacement therapy</a> may be useful for <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001195.htm\" target=\"_blank\">hypogonadism</a> in males</li>\r\n</ul>\r\n<p>Myotonia is usually mild and rarely requires treatment. Routine exercise appears to help with pain control, as well as with muscle strength and endurance. The effectiveness of most medications for pain management varies. <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607064.html\" target=\"_blank\">Mexilitene</a>, which is very effective for some forms of myotonia, has helped control muscle pain in some people with this condition. Other medications that have been used with some success include <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a694007.html\" target=\"_blank\">gabapentin</a>, nonsteroidal anti-inflammatory drugs (NSAIDS), low-dose thyroid replacement, low-dose steroids, and <a href=\"http://www.nlm.nih.gov/medlineplus/antidepressants.html\" target=\"_blank\">tricyclic antidepressants</a>. Cholesterol-lowering medications should be avoided when they are associated with increased weakness.[348]<br />\r\n<br />\r\nThere are steps a person can take to prevent some secondary complications. Anesthetic risk may be increased, so careful assessment of heart and respiratory function before and after surgery are recommended. Affected people should also have a yearly <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003868.htm\" target=\"_blank\">electrocardiogram</a> or cardiac MRI to detect possible conduction defects or cardiomyopathy.[348]<br />\r\n<br />\r\nYou can see <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1466/#myotonic-d2.Management\" target=\"_blank\">more detailed information about the management of myotonic dystrophy type 2 on the GeneReviews Web site</a>.</p>","dateModified":"2014-02-11T10:31:00","resourceClassificationName":"Treatment","references":[{"referenceId":348,"authors":"Dalton JC, Ranum LPW, and Day JW","articleTitle":"Myotonic Dystrophy Type 2","bookWebsiteJournalTitle":"GeneReviews","date":"July 3, 2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1466/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7299,"questionText":"What is the long-term outlook for people with myotonic dystrophy type 2?","answerText":"In general, people with myotonic dystrophy type 2 have a better long-term outlook (prognosis) than those with type 1. Symptoms are usually relatively mild. While the rate of progression can vary among affected people, symptoms generally progress slowly.[7172] While mobility may be impaired at an earlier age, the ability to walk is often retained until around 60 years of age.[7170][7172]<br />\r\n<br />\r\nThe prognosis for affected people can depend on the extent of heart (cardiac) involvement.[7170] While definitive information is not available, it appears there is relatively little shortening of the lifespan in people with myotonic dystrophy type 2.[7171]","dateModified":"2014-02-11T09:55:00","resourceClassificationName":"Prognosis","references":[{"referenceId":7170,"authors":"Fran√ßoise Bouhour","articleTitle":"Proximal Myotonic Myopathy","bookWebsiteJournalTitle":"Orphanet","date":"July, 2007","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=606","dateAccessed":"2014-02-10T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":7171,"authors":"David A Chad and Basil T Darras","articleTitle":"Myotonic dystrophy: Prognosis and management","bookWebsiteJournalTitle":"UpToDate","date":"January, 2014","volume":"","pages":"","url":"","dateAccessed":"2014-02-10T00:00:00","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"},{"referenceId":7172,"authors":"","articleTitle":"Myotonic muscular dystrophy","bookWebsiteJournalTitle":"Muscular Dystrophy Association","date":"","volume":"","pages":"","url":"http://mda.org/disease/myotonic-muscular-dystrophy/overview","dateAccessed":"2014-02-10T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":10419,"relatedDiseaseName":"Myotonic dystrophy","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":5624,"phenoTypeName":"Cataract","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14283,"phenoTypeName":"Myotonia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":3593,"phenoTypeName":"Decreased circulating IgG level","percentRanges":"-"},{"phenoTypeId":7941,"phenoTypeName":"Decreased circulating total IgM","percentRanges":"-"},{"phenoTypeId":14182,"phenoTypeName":"Diabetes mellitus","percentRanges":"-"},{"phenoTypeId":15572,"phenoTypeName":"Elevated circulating follicle stimulating hormone level","percentRanges":"-"},{"phenoTypeId":10933,"phenoTypeName":"Elevated serum creatine kinase","percentRanges":"-"},{"phenoTypeId":11390,"phenoTypeName":"Frontal balding","percentRanges":"-"},{"phenoTypeId":9728,"phenoTypeName":"Hypogonadism","percentRanges":"-"},{"phenoTypeId":1374,"phenoTypeName":"Insulin insensitivity","percentRanges":"-"},{"phenoTypeId":9612,"phenoTypeName":"Iridescent posterior subcapsular cataract","percentRanges":"-"},{"phenoTypeId":3980,"phenoTypeName":"Myalgia","percentRanges":"-"},{"phenoTypeId":5294,"phenoTypeName":"Neck flexor weakness","percentRanges":"-"},{"phenoTypeId":14167,"phenoTypeName":"Oligospermia","percentRanges":"-"},{"phenoTypeId":13063,"phenoTypeName":"Palpitations","percentRanges":"-"},{"phenoTypeId":5281,"phenoTypeName":"Proximal muscle weakness","percentRanges":"-"},{"phenoTypeId":8983,"phenoTypeName":"Tachycardia","percentRanges":"-"},{"phenoTypeId":6237,"phenoTypeName":"Type 2 muscle fiber atrophy","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Myotonic_dystrophy_type_2"}